Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib in NSCLC Patients With Brain Metastases
NCT05567055Phase 2Withdrawn
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
01
Overview
Phase 2, open-label, single-arm trial of capmatinib in non-small cell lung cancer (NSCLC). Primary endpoint: CNS Overall Response Rate up to 36 months. Planned start Oct 2023; status: withdrawn.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05567055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567055.